

## ASTRAZENECA PRICES A \$6 BILLION BOND ISSUE

AstraZeneca PLC announces that yesterday it conducted a global bond market transaction by issuing a total of \$6bn of notes. The proceeds of the issue will be used to fund the previously announced acquisition of ZS Pharma, Inc., to repay certain outstanding commercial paper obligations, and for general corporate purposes. The transaction, which is a global offering registered with the US Securities and Exchange Commission (SEC), consists of five tranches:

- \$0.4bn of 3-year floating rate notes;
- \$1.0bn of 3-year fixed rate notes with a coupon of 1.750%;
- \$1.6bn of 5-year fixed rate notes with a coupon of 2.375%;
- \$2.0bn of 10-year fixed rate notes with a coupon of 3.375%; and
- \$1.0bn of 30-year fixed rate notes with a coupon of 4.375%.

The notes will be issued under AstraZeneca's existing automatic shelf registration statement on Form F-3, which AstraZeneca filed with the SEC on 26 November 2013. Such registration statement provides for the offer and sale from time to time of an indeterminate amount of AstraZeneca's debt securities and includes a prospectus that investors should read to obtain more complete information. The offering was made solely by means of a written prospectus forming part of the effective registration statement.

A copy of the prospectus supplement and accompanying prospectus relating to the offering can be obtained by contacting Barclays Capital Inc. at +1 888 603 5847, HSBC Securities (USA) Inc at +1 866 811 8049, Merrill Lynch, Pierce, Fenner & Smith Incorporated at +1 800 294 1322 or Morgan Stanley & Co. LLC at +1 866 718 1649. You may also get these documents for free by visiting EDGAR on the SEC website at [www.sec.gov](http://www.sec.gov).

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

The bond issuance does not have any material impact to the Company's financial guidance for 2015.

11 November 2015

### About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information about AstraZeneca please visit: [www.astrazeneca.com](http://www.astrazeneca.com).

### CONTACTS

#### Media Enquiries

|                  |           |                  |
|------------------|-----------|------------------|
| Esra Erkal-Paler | UK/Global | +44 20 7604 8030 |
| Vanessa Rhodes   | UK/Global | +44 20 7604 8037 |
| Ayesha Bharmal   | UK/Global | +44 20 7604 8034 |
| Karen Birmingham | UK/Global | +44 20 7604 8120 |
| Jacob Lund       | Sweden    | +46 8 553 260 20 |
| Michele Meixell  | US        | +1 302 885 2677  |

#### Investor Enquiries

##### UK

|                  |                     |                  |                 |
|------------------|---------------------|------------------|-----------------|
| Thomas Kudsk     | Oncology            | +44 20 7604 8199 | +44 7818 524185 |
| Larsen           |                     |                  |                 |
| Eugenia Litz     | RIA                 | +44 20 7604 8233 | +44 7884 735627 |
| Nick Stone       | CVMD                | +44 1763 263 994 | +44 7717 618834 |
| Craig Marks      | Finance             | +44 20 7604 8591 | +44 7881 615764 |
| Christer Gruvris | Consensus Forecasts | +44 20 7604 8126 | +44 7827 836825 |

##### US

|                  |               |                 |                 |
|------------------|---------------|-----------------|-----------------|
| Lindsey Trickett | Oncology, ING | +1 301 398 5118 | +1 240 543 7970 |
| Mitch Chan       | Oncology      | +1 301 398 1849 | +1 240 477 3771 |
| Dial / Toll-Free |               | +1 301 398 3251 | +1 866 381 7277 |

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal